Low dose substance; probably insignificant hepatic exposure. Structural similarity to clonidine where there are conflicting references, several of which warn strictly.

Clonidine-like imidazole derivative.

Antihypertensive imidazoline derivative, given in a dose of 200-400 ug/d.

Daily dose is below 1 mg and therapeutic plasmaconcentrations seem normally well below 100nM. This exposure would not be enough to give rise to clinical porphyrinogenic effects.

About 50 to 75% of an oral dose is excreted as unchanged drug. No significant first passage metabolism. Oxidative liver metabolism occurs, but it has not been described which enzymes are involved. Approximately 10% to 20% of a dose is metabolised to 4,5-dehydroxymoxonidine and to a guanidine derivative by ring opening. No clinical observations of CYP interaction. Mainly eliminated by tubular excretion.

None.

None.

None.

Uneventful use reported in 1 patient with acute porphyria.